Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLI-ATG Conditioning for Allogeneic HCT in Older Patients
NCT00185640Phase 2Completed
- Sponsor
- Stanford University
- Start
- Mar 2003
- Primary completion
- Apr 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin in hematologic malignancy, non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL) and 7 more, sponsored by Stanford University. Primary endpoint: Acute Graft vs Host Disease at 100 days. Started Mar 2003; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
hematologic malignancynon-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00185640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00185640.